Search
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Gliosarcoma

NCT Trial Name# of Centers

NCT00892177

  Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
308

NCT01814813

  Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
286

NCT02152982

  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
273

NCT01648348

  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
242

NCT01781468

  Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
240

NCT01609790

  Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
175

NCT00329719

  Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
121

NCT01062399

  Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
36

NCT01730950

  Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
31

NCT02761070

  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
21

NCT01421524

  Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
21

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
18

NCT01026493

  Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
17

NCT02052648

  Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
16

NCT03115333

  DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
16

NCT02078648

  Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
16

NCT02343406

  Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE 2)
14

NCT02798406

  Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
13

NCT03389802

  Phase I Study of APX005M in Pediatric CNS Tumors
12

NCT01149109

  Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
12

NCT01514201

  Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
11

NCT02743078

  Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
11

NCT02658981

  Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
10

NCT02311920

  Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
10

NCT01836549

  Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
10

NCT01790503

  A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
9

NCT02337491

  Pembrolizumab +/- Bevacizumab for Recurrent GBM
8

NCT03107780

  MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma
8

NCT02903069

  Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
7

NCT02977780

  INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
7

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
7

NCT02101905

  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
7

NCT01402063

  PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
6

NCT00602667

  Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
6

NCT02852655

  A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
6

NCT03149575

  VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
5

NCT02330562

  Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
5

NCT02386826

  INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
5

NCT02455557

  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
5

NCT00879437

  Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
5

NCT01462695

  Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
5

NCT00859222

  LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
5

NCT01257594

  EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
4

NCT02768389

  Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
4

NCT02871843

  Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
3

NCT03137888

  Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
3

NCT03395587

  Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma
3

NCT01189266

  Vorinostat and Radiation Therapy Followed By Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Pontine Glioma
3

NCT01380782

  BIBF 1120 for Recurrent High-Grade Gliomas
3

NCT01445691

  More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
3

NCT00275067

  Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
3

NCT00766467

  A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
3

NCT01236560

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
3

NCT01149850

  Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
3

NCT01062425

  Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
2

NCT01435395

  Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
2

NCT01894061

  NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
2

NCT00890786

  A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
2

NCT01339039

  Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
2

NCT03139916

  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
2

NCT03383978

  Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)
2

NCT02340156

  Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
2

NCT02430363

  Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
2

NCT02137759

  MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
2

NCT01925573

  Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
1

NCT01977677

  Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
1

NCT01985087

  A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
1

NCT02015819

  Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
1

NCT02062827

  Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
1

NCT02197169

  DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
1

NCT01837862

  A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
1

NCT02331693

  CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
1

NCT02337426

  Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
1

NCT02337686

  Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
1

NCT02206230

  Trial of Hypofractionated Radiation Therapy for Glioblastoma
1

NCT02254954

  Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed GBM.
1

NCT02272270

  Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)
1

NCT02287428

  Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma
1

NCT02626364

  Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
1

NCT02394665

  MRSI Guided Dose Escalated Radiation in Glioblastoma
1

NCT02540161

  Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
1

NCT02192359

  Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
1

NCT02709226

  Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
1

NCT02648633

  Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
1

NCT02661282

  Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients
1

NCT03426891

  Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
1

NCT03119064

  BrUOG 329 GBM Onyvide With TMZ
1

NCT03283631

  Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
1

NCT03176160

  LITT Palliative Treatment for Patients With Malignant Gliomas
1

NCT03367715

  Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
1

NCT03400917

  Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
1

NCT03419403

  A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin
1

NCT03452930

  EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)
1

NCT00636805

  Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
1

NCT00734682

  A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
1

NCT01113398

  AMG 102 and Avastin for Recurrent Malignant Glioma
1

NCT03020017

  NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
1

NCT02805179

  A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
1

NCT03020602

  BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
1

NCT02942264

  TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
1

NCT03173950

  Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
1

NCT03174197

  Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)
1

NCT03197506

  Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
1

NCT03212742

  Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
1

NCT03251989

  Outcomes and Risk in People With Ependymoma
1

NCT03291314

  Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
1

NCT02991456

  Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
1

NCT03043391

  Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
1

NCT03344250

  Phase I EGFR BATs in Newly Diagnosed Glioblastoma
1

NCT03277638

  Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma
1

NCT00883298

  Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
1

NCT00805376

  Delta-24-RGD for Recurrent Malignant Gliomas
1

NCT01172964

  A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
1

NCT00995007

  A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
1

NCT00998010

  Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
1

NCT01051557

  Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
1

NCT01086345

  Radiosurgery Plus Bevacizumab in Glioblastoma
1

NCT01110876

  Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
1

NCT01130077

  A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
1

NCT01454596

  CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
1

NCT01479686

  iMRI Guided Resection in Cerebral Glioma Surgery
1

NCT01499251

  Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
1

NCT01582152

  Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
1

NCT01591577

  Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
1

NCT01639612

  Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
1

NCT01644955

  Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
1

NCT01119599

  RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
1

NCT01393912

  PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
1

NCT01430351

  Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)
1

NCT01434602

  Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
1

NCT01209442

  Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
1

NCT01266031

  Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
1

NCT01754350

  Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
1

NCT01954030

  Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
1

NCT01954576

  NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
1

NCT01867593

  MET-PET for Newly Diagnosed Glioblastoma
1

NCT01957956

  Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
1

NCT01989052

  Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
1

NCT01999270

  Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
1

NCT02006407

  A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
1

NCT02031965

  Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
1

NCT01903330

  ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
1

NCT02029573

  Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
1

NCT01517776

  Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
1

NCT01644773

  Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
1

NCT01721577

  Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
1

NCT01740258

  Bevacizumab Beyond Progression (BBP)
1

NCT01822275

  Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
1

NCT01854554

  Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
1

NCT01856933

  BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
1

NCT01124240

  Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
1

NCT01227434

  A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
1

NCT01260506

  Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
1

NCT00555399

  Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
1

NCT00669669

  O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
1

NCT01757652

  Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma
1

NCT01778530

  TRC105 for Recurrent Glioblastoma
1

NCT01931098

  Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)
0

Brain Tumor News Articles About Gliosarcoma

  1. [07/11/2020] Comparative Epidemiology of Gliosarcoma and Glioblastoma and the Impact of Race on Overall Survival: A Systematic Literature Review
    This is similiar to an article I posted a few weeks ago, both show that there is a large discrepancy in both clinical trial participation as well as overall survival by race.    This is not acceptable. We are working on leveling the playing field by collaborating with the Society of Neuro-oncology as well as a group of research and other organizations to remove barriers to participation in clinical trials. 
     
    Our copayment assistance program was a major help in this regard - as a major part of the survival difference is inability to afford treatments - however we ran out of money and our program is closed to new patients. We get calls every day asking for help and right now there are no copay programs open to help people on Temodar.  Many patients are sadly going without it.
     


  2. [01/07/2019] Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.

    They should have done this a long time ago. I hope this becomes available for patients soon.  The delivery method should be approved separately from the drugs used - so we can mix and match drugs based on a patients' genetic profile.

  3. [12/19/2016] Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.  Aside from the mechanism of action these authors proposed, perhaps the theories about cytomegalovirus playing a role in GBMs are valid, and this drug also fights the CMV, just like Valcyte does.

  4. [02/21/2016] Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.  I love this type of project.  These researchers tried adding the drug valganciclovir (Valcyte) to the treatment plan for recurrent gbm patients who were using Avastin. The concept behind this is that most or all GBMs have a virus in them called Cytomegalovirus. (Some researchers disagree and say NONE of the GBMs they tested have the virus).   It is not known if the virus triggers the tumor to form, or if it makes the tumor more aggressive, or if it is just a bystander and doesn't affect the tumor. Valcyte is an oral antiviral drug which slows or stops the virus from reproducing. This study (although it is too small to be considered proof) shows that adding Valcyte increases overall survival and progression free survival. This implies that the CMV plays a role in making the tumor grow. Using it in combination with Avastin was a great idea, since Avastin also slows down the tumor growth using a different pathway (VEGF).  I think that hitting either pathway alone allows the tumor to find a way around the treatment, but hitting it on multiple pathways may be the answer. Perhaps adding 1 or 2 other treatments, hitting the tumor from another pathway, may make even a larger difference.

  5. [10/02/2013] Long-term treatment with temozolomide in malignant glioma.   It never made sense to me to stop Temodar at 6 months. The reason they always give is that is the length of time used in the trial was 6 months so they use that. However, that 6 months was chosen to allow the trial to conclude quickly.  They never tested varying lengths of treatment against each other.   The other argument to end treatment early was increased chance of side effects. This article shows in a small group, that it is relatively safe to continue for an extended period of time.  There is also the risk of developing a secondary cancer - but that risk is smaller than the original tumor growing back and killing you.

  6. [05/23/2012] IBTA Newsletter

  7. [04/30/2012] Bevacizumab for GBM Linked to More Secondary Gliosarcomas Daniel M. Keller, PhD

  8. [04/27/2011] The natural history of extracranial metastasis from glioblastoma multiforme.

  9. [02/23/2011] Temozolomide in the treatment of high-grade gliomas in children: a report from the Children`s Oncology Group.

  10. [02/08/2011] A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

  11. [11/22/2010] Paclitaxel Poliglumex (OPAXIO®) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer

  12. [10/22/2010] New Clinical Study for Recurrent Glioblastoma Being Conducted at City of Hope: Neural Stem Cell Platform: First-In-Human Trials

  13. [04/28/2010] Patient Trial of Personalized Two-Drug Therapy for Brain Tumors Launched

  14. [03/16/2009] New vaccine trial opens for pediatric (ages 3 to 20) high grade, low grade and brainstem glioma

  15. [12/31/2008] Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma.

  16. [12/22/2006] $115,000 in grants awarded for brain tumor research!

  17. [11/22/2006] Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

  18. [06/07/2006] A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

  19. [05/02/2006] Interstitial Docetaxel (Taxotere), Carmustine and Combined Interstitial Therapy: a Novel Treatment for Experimental Malignant Glioma.

  20. [05/02/2006] Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation( bigstar).

  21. [04/18/2006] Lactacystin Exhibits Potent Anti-tumor Activity in an Animal Model of Malignant Glioma when Administered via Controlled-release Polymers.

  22. [01/11/2006] Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages.

  23. [01/05/2006] Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

  24. [05/11/2005] Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.

  25. [11/25/2004] Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.

  26. [08/04/2004] Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure

  27. [05/18/2004] Role of estrogen receptor-related antigen in initiating the growth of human glioma cells.

  28. [12/24/2003] A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation.

  29. [10/26/2003] Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

  30. [06/14/2003] Clinical outcome and distribution measure of a recombinant chimeric protein composed of transforming growth factor alpha and a mutated Pseudomonas exotoxin (TP-38) via convection-enhanced microinfusion on a phase I study for malignant brain tumor

  31. [06/14/2003] A phase II trial of temozolomide and oral VP-16 for adults with recurrent malignant glioma

  32. [05/22/2003] Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.

  33. [04/08/2003] Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.

  34. [04/01/2003] Characterization of Gastrin-induced Cytostatic Effect on Cell Proliferation in Experimental Malignant Gliomas.

  35. [04/01/2003] Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.

  36. [01/21/2003] The combination of X-ray-mediated radiosurgery and gene-mediated immunoprophylaxis for advanced intracerebral gliosarcomas in rats.

  37. [12/18/2002] Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy.

  38. [12/09/2002] Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.

  39. [05/26/2002] A phase I study of temozolomide (Temodar) and escalating doses of oral VP-16 for adults with recurrent malignant glioma The maximum tolerated dose of this combination in this heavily treated group of patients with recurrent malignant glioma is temozolomide 150 mg/m2/d for 5 days + oral VP-16 50 mg/m2/d for 12 days.





Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740